Eisai Wins U.S. FDA Post-Operative Indication For Antiemetic Aloxi
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has approved a new indication for Japan-based Eisai's Aloxi (palonosetron hydrochloride) for post-operative nausea and vomiting in the first 24 hours after surgery. The drug maker announced approval of the expanded indication March 3 for the drug it obtained through the acquisition of MGI Pharma earlier this year (PharmAsia News, Jan. 24, 2008).
You may also be interested in...
Aloxi GMP Problems May Trigger Import Controls
France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.
Aloxi GMP Problems May Trigger Import Controls
France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.
U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV
TOKYO - Eisai said Aug. 24 that it had obtained U.S. FDA approval for an oral capsule formulation of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and voting, broadening the company's reach into the CINV market